Treatment News : People Over 60 Respond Well to HIV Treatment

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » June 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

June 24, 2010

People Over 60 Respond Well to HIV Treatment

The vast majority of HIV-positive people older than 60 respond well to antiretroviral (ARV) therapy—achieving undetectable virus levels and substantial CD4 cell increases—according to a study published in the July 1 issue of the Journal of Acquired Immune Deficiency Syndromes.

Only a few large studies have documented how older HIV-positive people respond to ARV therapy compared with younger people living with the virus. Since experts project that more than half of HIV-positive people in the United States will be 50 and older by 2015, this lack of data is concerning—especially in light of the fact that some small studies have suggested that people who start ARVs at a later age might recover fewer CD4 cells.

To determine the impact of ARV therapy in older people, Luis Manrique, MD, and his colleagues at Rush University Medical Center in Chicago, reviewed the medical records of 191 people with HIV ages 60 and older. Manrique’s team separated the participants into two groups: 141 who were older than 50 at the time they were first diagnosed with HIV, and 50 who were 50 or younger at the time of diagnosis. The average age in the first group—those who’d been diagnosed after the age of 50—was 65, and the average duration of infection was eight years. The second group was slightly younger, on average, but had been infected for twice as long.

The two groups were similar in most respects, although the participants diagnosed when older than 50 were more likely to be coinfected with both HIV and hepatitis C virus (HCV). The older group also had lower CD4 counts before starting ARV treatment. Both groups, however, responded very well to treatment.

Seventy-six percent of the participants in both groups achieved undetectable virus levels after starting treatment. While groups also had significant increases in CD4 counts, with average increases of just less than 200 cells, those diagnosed after turning 50 had a trend toward poorer immune recovery.

There was a very high rate of coexisting medical conditions in both groups—68 percent had high blood pressure, 48 percent had high cholesterol, and roughly 25 percent had kidney disease or diabetes. The presence of these other medical conditions, however, did not appear to significantly reduce the positive impact of ARV therapy.

The authors note that the high treatment response rate was likely due at least in part to good adherence levels among those in the study, which confirmed previous research documenting better adherence among older people with HIV.

“Our single center study shows that with [ARV treatment], elderly HIV patients achieved successful immunologic and virologic outcomes despite a high rate of comorbidities,” concluded the authors. “The less robust [CD4] outcomes in older patients could be attenuated by earlier diagnosis and initiation of therapy.

“As this population ages,” they added, “the importance of managing other medical comorbidities will become increasingly important.”

Search: older, elderly, age, over 50, over 60, treatment, immune recovery, viral load, treatment response, Luis Manrique


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    CuteBoyinQns
    Jackson Heights
    New York


    soy_Ric
    Rochester
    New York


    cortaza100
    Chicago
    Illinois


    humboman
    Baltimore
    Maryland
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.